Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells $107,556.84 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director George A. Scangos sold 10,964 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total transaction of $107,556.84. Following the completion of the transaction, the director now owns 708,295 shares in the company, valued at approximately $6,948,373.95. This trade represents a 1.52 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Vir Biotechnology Trading Down 2.3 %

NASDAQ:VIR opened at $9.57 on Friday. Vir Biotechnology, Inc. has a fifty-two week low of $6.56 and a fifty-two week high of $14.45. The stock has a fifty day moving average price of $9.31 and a 200-day moving average price of $8.48.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of VIR. State Street Corp grew its stake in Vir Biotechnology by 10.4% during the third quarter. State Street Corp now owns 5,625,533 shares of the company’s stock worth $42,135,000 after buying an additional 530,645 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Vir Biotechnology by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 2,196,601 shares of the company’s stock worth $16,127,000 after acquiring an additional 7,827 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Vir Biotechnology by 58.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company’s stock worth $14,059,000 after acquiring an additional 703,360 shares in the last quarter. Millennium Management LLC increased its stake in Vir Biotechnology by 55.3% in the fourth quarter. Millennium Management LLC now owns 1,715,083 shares of the company’s stock valued at $12,589,000 after acquiring an additional 610,367 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Vir Biotechnology by 10.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,252,655 shares of the company’s stock valued at $9,194,000 after purchasing an additional 118,379 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

VIR has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a report on Wednesday, November 20th. Barclays reduced their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. HC Wainwright reiterated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Friday, January 31st. JPMorgan Chase & Co. lifted their target price on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a report on Thursday, January 9th. Finally, Morgan Stanley upgraded shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.83.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).